Zealand Pharma Will Test European IPO Market
This article was originally published in The Pink Sheet Daily
Executive SummaryThe Danish biotech hopes to tempt investors with revenue prospects from its late-stage GLP-1 analog, partnered with Sanofi-Aventis.
You may also be interested in...
The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.
French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes